Influence of hepatocarcinoma surveillance programs on cirrhotic patient’s survival: a real life study.

• F Fernández García ; JP Toro Ortiz ^[1] ; JM Pinazo Bandera ^[1] ; Ramiro Alcántara Benítez ; Aida Ortega Alonso ; Mercedes Robles Díaz ; Raúl J. Andrade Bellido ; Miren García Cortés
  1. [1] Hospital Universitario Virgen de la Victoria

     Hospital Universitario Virgen de la Victoria

     Málaga, España

     
• Localización: Revista andaluza de patología digestiva, ISSN 1988-317X, Vol. 45, Nº. 2, 2022, págs. 44-54
• Idioma: español
• Enlaces
  • Texto completo
• Resumen

  • Background: Hepatocellular carcinoma (HCC) represents 75%-85% of all primary liver cancers and the third most common cause of cancer-related death worldwide. Cirrhosis is the most relevant risk factor for HCC with 70%-90% of cases diagnosed at end-stage liver disease. Several studies have revealed that early diagnosis of HCC under surveillance improves both prognosis and availability of major curative options.

    Aim: to determine current HCC surveillance impact on survival at a university hospital.

    Methods: we retrospectively gathered all HCC diagnosed between Jan 2012 and May 2018 at a university hospital in Málaga(Spain). Inclusion criteria were all space-occupying lesions (SOL) diagnosed at our centre and exclusion criteria were all non-HCC SOL and HCC diagnosed before or after the given dates. Epidemiological, etiological, liver-function, clinical, tumor-related, therapeutic and response-to-treatment variables were collected.

    Results: 159 patients were finally included. 92.5% of HCC were diagnosed on cirrhotic patients. Following the Barcelona Clinic Liver Cancer (BCLC) staging classification, 73% of patients who underwent surveillance were diagnosed on 0, A or B stages, whereas 38% of patients who didn’t perform surveillance were diagnosed on given stages. The surveillance-applying cluster had a 33 months survival median while the not-surveillance cohort showed a survival of 6 months. The median survival on early stages (0 and A) [50 months], stage B (20 months), stage C (10 months) and stage D (2 months) showed statistically significant differences.

    Conclusions: HCC surveillance programs allow early diagnosis on favorable tumor stages, increasing chances of major treatment options, and life expectancy of patients.